https://www.cancerresearchuk.org/about-cancer/treatment/drugs/epcoritamab
Epcoritamab (Tepkinly) | Cancer Research UK
Epcoritamab is a type of targeted cancer drug for certain types of high grade B cell lymphoma. Find out about how you have it, possible side effects and other...
cancer researchepcoritamabtepkinlyuk
https://www.cigna.com/knowledge-center/hw/medications/epcoritamab-bysp-injection-a623023
Epcoritamab-bysp Injection | Cigna
Epcoritamab-bysp is used for treatment of diffuse large B-cell lymphoma (DLBCL; a type of cancer that impacts the lymphatic [infection-fighting] system in the...
epcoritamab byspinjectioncigna
https://www.hmpgloballearningnetwork.com/site/frmc/news/fixed-duration-epcoritamab-plus-r2-shows-strong-outcomes-rr-follicular-lymphoma
Fixed-Duration Epcoritamab Plus R2 Shows Strong Outcomes in R/R Follicular Lymphoma
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or...
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell...
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
https://www.hmpgloballearningnetwork.com/site/frmc/news/patient-outcomes-after-epcoritamab-or-glofitamab-failure-relapsed-or-refractory-lbcl
Patient Outcomes After Epcoritamab or Glofitamab Failure in R/R LBCL
Disease progression after treatment with bispecific antibodies such as glofitamab in relapsed or refractory large B-cell lymphoma (R/R LBCL) is associated with...
patient outcomesepcoritamabglofitamabfailure
https://www.medlineplus.gov/druginfo/meds/a623023.html
Epcoritamab-bysp Injection: MedlinePlus Drug Information
Epcoritamab-bysp Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus
epcoritamab byspinjectionmedlineplusdruginformation
https://www.hmpgloballearningnetwork.com/site/frmc/news/outpatient-epcoritamab-dosing-feasible-rr-dlbcl-study-finds
Outpatient Epcoritamab Dosing Feasible in R/R DLBCL, Study Finds
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory...
outpatientepcoritamabdosingfeasibledlbcl
https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL4650393
Compound: EPCORITAMAB (CHEMBL4650393) - ChEMBL
Report card for Compound EPCORITAMAB (CHEMBL4650393). Antibody, EPCORITAMAB, EPCORITAMAB-BYSP, EPKINLY, GEN-3013, GEN3013, TEPKINLY.
compoundepcoritamabchembl
https://www.medicines.org.uk/emc/ingredient/3432
Medicines containing the active ingredient epcoritamab - (emc)
Medicines containing the active ingredient epcoritamab
the activemedicinescontainingingredientepcoritamab
https://medlineplus.gov/druginfo/meds/a623023.html
Epcoritamab-bysp Injection: MedlinePlus Drug Information
Epcoritamab-bysp Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus
epcoritamab byspinjectionmedlineplusdruginformation
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma...
On June 26, 2024, the Food and Drug Administration granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3...
https://www.cancer.gov/about-cancer/treatment/drugs/epcoritamab-bysp
Epcoritamab-bysp - NCI
Epcoritamab-bysp works by bringing healthy T cells (immune cells that help kill cancer cells) and lymphoma cells close together so the T cells can more...
epcoritamab byspnci
https://www.mayo.edu/research/clinical-trials/cls-20570736
Epcoritamab Compared To Observation For Treating B-cell Lymphoma Patients Not In Complete Remission...
Learn more about services at Mayo Clinic.
https://www.mskcc.org/cancer-care/clinical-trials/25-219
A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab in People With Follicular Lymphoma |...
Full Title A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for treatment of relapsed or refractory follicular lymphoma or marginal zone...
https://www.mskcc.org/cancer-care/clinical-trials/25-032
A Phase 1b Study of Epcoritamab and Ibrutinib Given Together in People With Central Nervous System...
Full Title A Phase Ib trial with Dose Expansion of Epcoritamab in Combination with Ibrutinib in Refractory/Recurrent CNS lymphoma (EIFEL-Trial) Purpose...